Ambio, Inc., a pioneering biotechnology company specializing in the development of innovative peptide drugs, biosimilars, bioequivalents, and other intricate generic drugs, announced today that the U.S. Food and Drug Administration

Fujirebio Holdings, Inc. and Sysmex Corporation jointly announced today the expansion of their contract development and manufacturing services

SciNeuro Pharmaceuticals, a biotech company in the clinical stage, has successfully concluded dosing in its Phase 1 study, focusing on the development of treatments for neurodegenerative diseases

ASC Therapeutics, a privately-owned biopharmaceutical company specializing in the development of in-vivo gene replacement, gene editing, and allogeneic cell therapies

REGENXBIO Inc. celebrated a major milestone as the first patient received RGX-202 at dose level 2 in the Phase I/II AFFINITY DUCHENNE® trial. This trial is investigating RGX-202, a novel

Ensysce Biosciences, Inc. and OncoZenge AB have recently announced the signing of a letter of intent (LOI) to explore a strategic collaboration for the accelerated

TOLREMO therapeutics AG has announced the initiation of its Phase 1 clinical trial, with the dosing of the first patient taking place. This trial is designed to assess the safety, tolerability,

Recce Pharmaceuticals Limited has officially received approval from the Canadian Patent Office for a new patent titled "Process for Preparation of Biologically Active Copolymer

Arcturus Therapeutics Holdings Inc. has recently announced that the U.S. Food and Drug Administration granted Orphan Drug Designation for ARCT-032, the company's product candidate for treating cystic fibrosis

Hemogenyx Pharmaceuticals plc has made a noteworthy expansion in the potential applications of its Chimeric Bait Receptor platform. Initially designed for treating viral diseases

Simcere Pharmaceutical Group Limited recently finalized an exclusive license and collaboration agreement with Connect Biopharma HongKong Limited concerning Rademikibart, an innovative IL-4Rα monoclonal antibody

Immutep Limited has expanded the INSIGHT-003 trial to include four sites across Germany, including the University Clinic of Ruhr Universität Bochum and the Lung Clinic Cologne-Merheim

Immutep Limited has expanded the INSIGHT-003 trial to include four sites across Germany, including the University Clinic of Ruhr Universität Bochum and the Lung Clinic Cologne-Merheim.

BeiGene, Ltd. and Ensem Therapeutics, Inc. have disclosed a strategic collaboration, wherein BeiGene will acquire an exclusive global license for an Investigational New Drug

MIRA Pharmaceuticals, Inc., has unveiled a strategic collaboration with MIRALOGX, LLC, an intellectual property holding company established by MIRA's founder. This partnership grants MIRA exclusive development

HOOKIPA Pharma Inc, a company focused on developing immunotherapeutics using its proprietary arenavirus platform, has received FDA clearance for its Investigational New Drug

Avistone Biotechnology Co. Ltd. has recently gained conditional approval from the National Medical Products Administration to market Vebreltinib, a precision oncology therapeutic,

Lighthouse Pharmaceuticals, a clinical-stage biopharmaceutical company focused on precision medicine for Alzheimer's and other age-related diseases, has announced that the U.S. Food and Drug Administration

Axxam S.p.A. and Momentum Biotechnologies have recently formed a partnership to deliver innovative drug discovery solutions for clients in the biotechnology and pharmaceutical industries. The collaboration involves making Axxam's

Athira Pharma, Inc., recently unveiled promising preclinical data on fosgonimeton, a potential breakthrough in the treatment of Alzheimer's disease and other neurodegenerative conditions.

Ardelyx, Inc., is a biopharmaceutical company dedicated to discovering, developing, and commercializing innovative medicines to address unmet medical needs. The company recently announced that the U.S. Food and Drug Administration

Alvotech and JAMP Pharma Group have jointly announced that Health Canada has granted marketing authorization to JAMP Pharma for AVT04, a biotech analogue of Stelara (ustekinumab) developed by Alvotech.

Cerevance, a company dedicated to advancing precision therapeutics for central nervous system disorders, has recently initiated the Phase 2 clinical study of CVN424 in individuals diagnosed with early-stage Parkinson's disease

Legend Biotech Corporation has recently announced a significant development - its wholly-owned subsidiary, Legend Biotech Ireland Limited, has entered into an exclusive global license agreement with Novartis Pharma AG

Alvotech and STADA Arzneimittel have received a favorable opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency

Andelyn Biosciences, Inc., a forward-thinking Contract Development and Manufacturing Organization

BioRay Pharmaceutical Co. has commenced the Phase I clinical trial for BRY812, an innovative antibody-drug conjugate targeting LIV-1, a zinc transporter associated with cell growth in advanced malignancies.

LAPIX Therapeutics, Inc., a biopharmaceutical company dedicated to the development of innovative orally deliverable therapies for autoimmune diseases, has initiated the Phase 1 clinical trial for its LPX-TI641 therapy

BostonGene, a leading provider of AI-driven solutions for molecular and immune profiling, has announced a collaboration with LegoChem Biosciences, Inc. (LCB), a clinical-stage biopharmaceutical company specializing in the development

Acorda Therapeutics, Inc, has made an announcement regarding new regulatory submissions for the approval of INBRIJA® (levodopa inhalation powder) in six Latin American countries through its partner,

Halozyme Therapeutics, Inc, has recently announced a global collaboration and non-exclusive license agreement with Acumen Pharmaceuticals. This partnership grants Acumen access to Halozyme's ENHANZE® drug delivery technology,

BioCina Pty Ltd., a globally renowned biologics contract development and manufacturing organization, has recently announced an expanded partnership with GPN Vaccines Ltd. GPN Vaccines is a biotechnology company focused on developing Gamma-PN™

Immutep Limited has released new biomarker data from its Phase II trial, in which they investigated eftilagimod alpha, a soluble LAG-3 protein and first-in-class MHC Class II agonist administered subcutaneously. This trial examined efti in conjunction

Regulus Therapeutics Inc. is a biopharmaceutical company that focuses on the discovery and development of innovative medicines targeting microRNAs. The company, also known as Regulus,

Bayer and the Broad Institute of MIT and Harvard recently announced the extension of their research partnership for another five years, following a decade of successful collaboration. This renewed agreement

Kyverna Therapeutics, a clinical-stage company specializing in cell therapy and focused on developing innovative treatments for severe autoimmune diseases, has recently entered into a multi-year research funding agreement

Prelude Therapeutics Incorporated and AbCellera have recently unveiled a multi-year, multi-program partnership aimed at the exploration, advancement, and market launch of innovative treatments for cancer patients.

Chimeric Therapeutics, an Australian leader in cell therapy, announced today that the U.S. Food and Drug Administration has cleared the Investigational New Drug application for CHM 2101, the company's first-in-class CDH17 CAR T cell therapy

Oncoinvent AS, a company in the clinical stage focused on advancing alpha emitter therapy for various solid cancers, has officially received approval from the U.S. Food and Drug Administration for its Investigational New Drug

Transpire Bio's commitment to Florida and the establishment of a biomanufacturing workforce in Weston. She envisioned this move as a potential opportunity to position South Florida at the forefront of the life sciences industry.

AnHeart Therapeutics, a global clinical-stage biopharmaceutical company, has recently established an exclusive license agreement with Nippon Kayaku Co., Ltd for the marketing and distribution of their lead investigational therapy.

Biophytis SA, a biotechnology company in the clinical development stage listed on Nasdaq CM and Euronext Growth Paris, specializes in the development of therapeutics aimed at slowing the degenerative processes associated with aging and improving

Oncternal Therapeutics, Inc, is a clinical-stage biopharmaceutical company dedicated to developing novel oncology treatments. They recently announced that the U.S. Food and Drug Administration has granted Fast Track designation for ONCT-534.

Simbec-Orion, a mid-sized Contract Research Organization, and biotx.ai, a company specializing in AI-powered causal modeling for drug development, have officially revealed their strategic partnership

ReHeva Biosciences, an innovative biopharmaceutical startup, is thrilled to announce the successful completion of its Phase I Safety Trial for its groundbreaking drug, RH324. This achievement represents a major milestone in the company's

Turbine, a computational biology company specializing in empirically validated in silico cell simulations for guiding biopharmaceutical research and development, has announced a collaborative partnership

Elektrofi, Inc., a biopharmaceutical formulation technology company specializing in strategic partnerships to revolutionize the delivery of biologic therapies, has announced a multi-target research collaboration and license agreement with Eli Lilly

Ankyra Therapeutics, a clinical-stage biotechnology company pioneering anchored immunotherapies for cancer treatment, has received approval for its investigational new drug application from the U.S. Food & Drug Administration

Kiromic BioPharma, Inc. has made a significant announcement regarding its clinical initiatives. The company, a pioneer in the field of biotherapeutics, is utilizing its exclusive DIAMOND® artificial intelligence

Iksuda Therapeutics, a company specializing in the development of innovative antibody drug conjugates with enhanced tumor specificity, has announced a significant milestone in its clinical trials. The first patient has successfully completed the initial treatment cycle of IKS014, an antibody-drug

Amgen, a company listed on NASDAQ under the symbol AMGN, has unveiled the findings from the global Phase 2 DeLLphi-301 study. This study assessed the efficacy of tarlatamab

Rise Therapeutics, a biotechnology company specializing in the development of novel oral immunotherapeutics, has announced that the U.S. Food and Drug Administration has approved its investigational new drug

Qnovia, Inc., a pharmaceutical company specializing in the development of inhaled therapeutic products across various medical fields, has announced a collaborative effort with the University of Virginia to advance innovative inhaled drug candidates

Mablink Bioscience, a biotechnology company that focuses on advancing next-generation antibody-drug conjugates through its proprietary PSARLink™ platform, has announced its acquisition by Eli Lilly and Company.

Vaxcyte, Inc, has announced that the U.S. Food and Drug Administration has granted approval for the company's Investigational New Drug application for VAX-31, a 31-valent pneumococcal conjugate vaccine

Bolt Biotherapeutics has initiated its first-in-human Phase 1/2 clinical trial by dosing the inaugural patient with BDC-3042, a monoclonal antibody designed to repolarize tumor-associated macrophages (TAMs) for the purpose of combating cancer

SOTIO, a clinical-stage immuno-oncology company owned by PPF Group, has recently entered into a license and option agreement with Synaffix B.V., a subsidiary of Lonza, to develop next-generation antibody-drug

Nona Biosciences, a global pioneer of technology innovation and antibody discovery and development solutions, and INGENIA Therapeutics, a preclinical-stage biotech company

Mundipharma and Cidara Therapeutics (Nasdaq: CDTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has

AGC Biologics , a leading global biopharmaceutical contract developer and manufacturer (CDMO), today announced the completion of facility expansion for its new plasmid DNA (pDNA)

Cyrano Therapeutics, Inc., a regenerative medicine company pioneering the development of treatments for smell loss, announced today that it has commenced enrollment in the Phase 2

Lucy Therapeutics (LucyTx) has obtained additional funding from the International Rett Syndrome Foundation (IRSF) to support innovative treatments for individuals, both children and adults, grappling with Rett syndrome. This funding will also contribute to the expansion of LucyTx's pioneering treatment platform.

Eurofins CDMO Alphora Inc. announces that it has received its Health Canada Cannabis Drug License issued within the Cannabis Act and Cannabis Regulations for its Oakville, Ontario operations in September 2023. This compliments the Institutional Research License obtained through Health Canada in June 2021 for its Mississauga development site and a Standard Processing License obtained for the Oakville, Ontario manufacturing operation in May 2022.

Gritgen Therapeutics Co., Ltd., a biotechnology company specializing in the discovery and development of cutting-edge gene therapy products, is pleased to announce the successful validation and official commencement of operations at its commercial Good Manufacturing Practices (GMP) facility located in Suzhou Industrial Park.

Fujirebio Holdings, Inc. (Headquarters: Minato-ku, Tokyo; President & CEO: Goki Ishikawa) and Sysmex Corporation (Headquarters: Kobe, Japan; President: Kaoru Asano) jointly announce a Basic Agreement on Business Collaboration to foster a multifaceted partnership encompassing research and development, production, clinical development, and sales-marketing in the field of immunoassay.

Thermo Fisher Scientific, the global leader in scientific services, has announced an expansion of its manufacturing capacity in St. Louis, aimed at supporting the production of biologic therapies for a wide range of diseases, including cancer, autoimmune conditions, and rare genetic disorders.

Wheeler Bio, a contract development and manufacturing organization (CDMO) specializing in next-gen protein therapeutics, is pleased to announce the inauguration of its cutting-edge Current Good Manufacturing Practices (CGMP) drug substance facility located in the Ziggurat building (Echo Investment Capital) in Oklahoma City, OK.

GC Biopharma Corp. has officially announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to its drug candidate, GC1126A, for the treatment of Thrombotic Thrombocytopenic Purpura (TTP). This significant development was finalized on September 27.

Shasqi, a clinical-stage biotech company specializing in improving the effectiveness of cancer drugs using click chemistry, has announced an expansion of its ongoing research collaboration with Johnson & Johnson Enterprise Innovation Inc.

DelNova has announced a partnership with Pace® Life Sciences to serve as its contract development and manufacturing organization (CDMO). This collaboration will enable DelNova to advance the clinical development of its lead candidate

BostonGene, a prominent provider of AI-based molecular and immune profiling solutions, has announced a master agreement with Johns Hopkins University School of Medicine (JHUSOM) to collaborate on multiple clinical research projects. This partnership enables BostonGene and JHUSOM to further explore and validate innovative precision medicine approaches.

Meitheal Pharmaceuticals, Inc., a fully integrated generic injectables company headquartered in Chicago, has expanded its portfolio of generic injectable products through an asset purchase agreement made by its parent company, Hong Kong King-Friend Industry Co., (HKF). This agreement has increased Meitheal's total portfolio of generic injectables to include 82 products.

Natera, a global leader in cell-free DNA testing, has submitted the first module of its premarket approval (PMA) application to the U.S. Food and Drug Administration (FDA) for Signatera. Signatera is Natera's personalized and tumor-informed molecular residual disease (MRD) test,

Advent International and Warburg Pincus have successfully completed their acquisition of Baxter International Inc.'s BioPharma Solutions (BPS) business.

Promontory Therapeutics Inc., a clinical-stage biotechnology company specializing in immunogenic small molecule approaches in oncology, has achieved the distinction of being the first international company to gain membership in the Paris-Saclay Cancer Center (PSCC).

Oragenics, Inc. (NYSE American: OGEN) has entered into a significant partnership with Lantern Bioworks, marked by the formalization of a materials transfer agreement. This collaboration follows rigorous testing and validation of biological samples from Oragenics.

Orsini Specialty Pharmacy has been chosen by Amicus Therapeutics as the provider for Pombiliti™ (cipaglucosidase alfa-atga) and Opfolda™ (miglustat), a combination treatment approved for specific patients with late-onset Pompe disease.

Mabwell, an innovative biopharmaceutical company with an entire industry chain, has announced that the first patient has been dosed in a phase Ib/II trial of its novel Nectin-4 targeting ADC (R&D code: 9MW2821) in combination with a PD-1 inhibitor for the treatment of locally advanced or metastatic urothelial carcinoma.

Everest Medicines has received approval from the Taiwan Food and Drug Administration (TFDA) for its New Drug Application (NDA) for XERAVA® (eravacycline).

Calliditas Therapeutics AB has received orphan drug designation (ODD) from the US Food and Drug Administration (FDA) for its drug setanaxib for the treatment of Alport syndrome.

Nexus Pharmaceuticals, LLC has announced its receipt of approval from the U.S. Food and Drug Administration (FDA) for Fluorescein Injection, USP. Usman Ahmed, President and Chief Executive Officer of Nexus Pharmaceuticals, expressed enthusiasm about this FDA approval, stating

Chrysalis BioTherapeutics, Inc. has received permission from the U.S. Food and Drug Administration (FDA) to commence human clinical trials focused on treating acute lung failure. With the approval of its Investigational New Drug (IND) Application

AcuraStem, a biotechnology company focused on developing treatments for neurodegenerative diseases, has entered into a licensing agreement with Takeda to collaborate on the development and commercialization of AcuraStem's PIKFYVE targeted therapeutics, including AS-202, an antisense oligonucleotide (ASO) designed for the treatment of Amyotrophic Lateral Sclerosis (ALS).

Chime Biologics, a prominent Contract Development and Manufacturing Organization (CDMO) specializing in biologics, has entered into a strategic cooperation agreement with Kings Pharm. Under this agreement, Chime Biologics will utilize its extensive expertise in biosimilar projects to provide Kings Pharm

The U.S. Food and Drug Administration (FDA) has approved Jardiance® (empagliflozin) 10 mg tablets to reduce the risk of sustained decline in estimated glomerular filtration rate (eGFR)

Shanghai Henlius Biotech, Inc. (2696. HK) announced that the new drug application (NDA) for new indication of HANSIZHUANG (serplulimab injection), an innovative anti-PD-1 monoclonal antibody

Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical firm specializing in innovative inhaled therapies for serious pulmonary and central nervous system disorders, has announced that the U.S. Food and Drug Administration (FDA) has accepted the investigational new drug (IND) application for PUR3100 and issued a study may proceed letter.

Brain diagnostics innovator BrainScope has secured new investment from the Alzheimer’s Drug Discovery Foundation (ADDF) as part of its ongoing Series B equity financing round. This investment will support the development of an Artificial Intelligence / Machine Learning-derived brain-activity-based biomarker aimed at predicting the future onset of Alzheimer’s disease.

Unravel Biosciences, Inc. (referred to as "Unravel") has unveiled a pioneering initiative known as rareSHIFT™, aimed at expediting patient-centric drug discovery and translation with unmatched speed.

ST Pharm recently celebrated the completion of its groundbreaking ceremony, marking a significant stride in its efforts to expand its oligonucleotide manufacturing capacity and capabilities.

Following FDA authorization and CDC recommendation, Rite Aid (NYSE: RAD) has announced that eligible customers can now schedule appointments to receive the updated COVID-19 (2023-2024) vaccines at its locations and Bartell Drugs locations in the Pacific Northwest. Appointments are available starting on Friday, September 22.

Daiichi Sankyo (TSE: 4568) has announced that quizartinib has received a favorable recommendation for approval in the European Union (EU). This approval is for its use in combination with standard cytarabine and anthracycline induction, as well as standard cytarabine consolidation chemotherapy.

Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF), a North American biopharmaceutical company dedicated to the development of patient-centric medications for orphan and rare diseases, has announced a significant update.

Acticor Biotech (ISIN: FR0014005OJ5 - ALACT), a clinical-stage biopharmaceutical company developing glenzocimab, an innovative drug for treating cardiovascular emergencies, has announced its refined development plan for Acute Ischemic Stroke (AIS) aimed at obtaining glenzocimab's registration in Europe and the United States.

Biosyngen Pte Ltd (referred to as "Biosyngen") has announced that the U.S. FDA has granted clearance for the Investigational New Drug (IND) application for the Phase I/II clinical trial of BRL03.

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company dedicated to discovering and developing targeted therapeutics, has initiated a Phase 1 monotherapy expansion in its first-in-human clinical trial assessing IDE161 (NCT 05787587).

Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a global biotechnology company specializing in novel antibody therapeutics, has entered into a significant agreement with Myricx Bio, a British biotechnology company focused on creating a new class of cytotoxic payloads specifically designed for antibody-drug conjugates (ADCs).

Mabwell (Stock Code: 688062.SH) is an innovative biopharmaceutical company with a comprehensive presence in the pharmaceutical industry value chain. The company is dedicated to providing more effective and accessible therapies and innovative medicines to meet global medical needs.

Verily, a subsidiary of Alphabet specializing in precision health technology, and Kyverna Therapeutics, a clinical-stage cell therapy company focused on developing therapies for autoimmune diseases, have announced a multi-year collaboration aimed at identifying novel biomarkers and innovating clinical trial design and execution.

Nanostics Inc., a precision health company specializing in diagnostic tests developed with its ClarityDX® platform technology, has announced that the College of Physicians and Surgeons of Alberta (CPSA) has granted provisional accreditation to Nanostics Clinical Laboratory in Edmonton, Alberta, Canada.

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, has unveiled new data showcasing the potent in vitro activity of NRX-101 (D-cycloserine + lurasidone) against reference strains of urinary tract pathogens known to cause complicated urinary tract infections (cUTIs)

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) has announced its receipt of Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for calcium gluconate in sodium chloride injection, specifically in 1000 mg/50 mL and 2000 mg/100 mL formulations. This injectable product is currently listed on the U.S. FDA shortage product list.

PsychoGenics Inc. (PsychoGenics) and Collaborations Pharmaceuticals, Inc. (CPI) are excited to announce the receipt of a $1 million Phase I Small Business Innovation Research (SBIR) grant. This grant represents a significant step forward in their collaboration, which seeks to utilize their combined AI capabilities to develop innovative drugs for mental health disorders.

XtalPi, a leader in AI-driven drug discovery, and Parthenon Therapeutics, a biotech firm focused on reshaping the tumor microenvironment, have announced a collaboration to develop new therapeutic antibodies for treating solid tumors.

Korean clinical trial sample analysis company, GCCL, announced on September 5th that it has implemented the Lab Information Management System (LIMS) for the first time in the sample analysis industry.

Seagen Inc. (Nasdaq: SGEN) and Genmab A/S (Nasdaq: GMAB) have jointly announced the positive results from the Phase 3 innovaTV 301 global trial, which focused on recurrent or metastatic cervical cancer patients with disease progression after initial therapy.

INtRON Biotechnology, a biotech company, has announced a formal contract between its New Drug Part and the U.S. Army DEVCOM (U.S. Army Combat Capabilities Development Command) International Technology Center Indo-Pacific and Soldier Center. The contract aims to collaborate on the development of bacteriophages for combatting Uropathogenic Escherichia coli (UPEC) infections.

Amgen (NASDAQ: AMGN) and Horizon Therapeutics plc (NASDAQ: HZNP) have jointly announced the execution of a consent order agreement with the Federal Trade Commission (FTC) as a resolution to the ongoing FTC administrative lawsuit. This agreement paves the way for the final steps toward completing Amgen's acquisition of Horizon.

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKEX: 02315) is pleased to announce the formal establishment of two significant business divisions, each representing distinct aspects of the company's comprehensive product, service, and asset portfolio.

Twist Bioscience Corporation (NASDAQ: TWST) has unveiled a significant drug discovery partnership with Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President and CEO: Gyo Sagara; "Ono") aimed at the development of novel antibodies for treating autoimmune diseases.

Serina Therapeutics, Inc. (referred to as "Serina"), a clinical-stage biotechnology firm dedicated to developing therapies for Parkinson's Disease and other neurological disorders, has entered into a merger agreement with AgeX Therapeutics, Inc. (NYSE American: AGE), a publicly traded biotechnology company, on August 29, 2023.

Cybin Inc. a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, and Small

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company dedicated to advancing cancer treatment and prevention, has initiated the treatment of the third participant in collaboration with Moffitt Cancer Center as part of an ongoing clinical trial for its innovative chimeric antigen receptor T-cell (CAR-T) therapy designed for ovarian cancer.

Allucent, a prominent global mid-sized clinical research organization (CRO), has been designated by the Biomedical Advanced Research and Development Authority

Zhiyi Biotech has announced the initiation of the U.S. Phase 1 clinical trial for their innovative product SK10, which is aimed at addressing Chemotherapy-induced Diarrhea (CID). The trial marks a significant milestone as the first three subjects have been successfully dosed. SK10 is a heat-killed Bacteroides fragilis product developed by Zhiyi Biotech.

Altogen Labs, a preclinical Contract Research Organization (CRO) laboratory, has announced the successful validation of a comprehensive array of 10 lung cancer xenograft models.

MapLight Therapeutics, a clinical-stage biopharmaceutical company specializing in the development of targeted therapeutics for brain disorders, has successfully completed a second Phase 1 clinical trial assessing the safety and efficacy of ML-007, a novel M1/M4 muscarinic receptor agonist.

Everest Medicines, a biopharmaceutical company dedicated to developing, manufacturing, and commercializing innovative medicines and vaccines, has announced that the Pharmaceutical Administration Bureau of the Macao Special Administrative Region, China, has accepted its New Drug Application (NDA) for Nefecon®.

SimBioSys, a pioneering TechBio company leveraging Artificial Intelligence (AI), spatial biophysics, and data science to redefine precision medicine and combat cancer, proudly announces its role as one of the founding members of the CancerX initiative.

AGC Biologics, a prominent global biopharmaceutical contract development and manufacturing organization (CDMO), has unveiled the expansion of its Longmont, Colorado facility with the addition of three state-of-the-art Grade B cell therapy manufacturing facilities.

Paradigm Therapeutics Inc., a biopharmaceutical company, has successfully finalized the acquisition of the global rights for SD-101, a topical whole-body treatment for all subtypes of Epidermolysis Bullosa (EB), from Amicus Therapeutics. The specifics of the agreement have not been publicly disclosed.

LEO Pharma has officially announced a strategic move to acquire Timber Pharmaceuticals, Inc., a company listed on the NYSE American under the ticker symbol TMBR.

Enveric Biosciences (NASDAQ: ENVB), a biotech firm dedicated to pioneering innovative neuroplastogenic small-molecule therapeutics aimed at addressing anxiety, depression, and addiction disorders, has recently achieved a significant milestone.

Everest Medicines (HKEX: 1952.HK) has announced that the U.S. Food and Drug Administration (FDA) has accepted the submission for the supplemental New Drug Application (sNDA) for Nefecon® from its partner Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) and has granted Priority Review.

Reykjavik-based pharmaceutical discovery company, 3Z, has partnered with causal AI firm biotx.ai, based in Germany and the US, with the aim of revolutionizing the development of drugs for ADHD. Through the integration of advanced AI modeling techniques, this collaboration seeks to bridge the gap between animal-based studies and human clinical trials, facilitating a more precise and efficient translation of promising therapies.

Response Pharmaceuticals, Inc. today announced the successful completion of its Phase 1B clinical trial for the company's lead drug candidate, RDX-002, a first-in-class inhibitor of intestinal

Neurophth Therapeutics, Inc. announced today that the first patient has been dosed in the international multi-region, multi-center Phase I/II clinical trial for the treatment of Leber hereditary

Boston Immune Technologies and Therapeutics, Inc. (BITT), a biotechnology company in the clinical stage, has announced that its Investigational New Drug application (IND) for BITT2101 (anti-TNFR2), a novel tumor necrosis factor superfamily receptor (TNFSR) antagonist antibody

CervoMed Inc. (formerly Diffusion Pharmaceuticals Inc.) (NASDAQ: CRVO), now a clinical-stage company focused on developing treatments for degenerative brain diseases, has successfully completed its previously announced merger with EIP Pharma Inc.

Tigermed (300347.SZ/3347.HK), a prominent global Contract Research Organization (CRO) offering comprehensive research and development solutions for the biopharmaceutical and medical device sectors, has officially inaugurated its International Headquarters in Hong Kong.

We are pleased to announce a fresh collaboration with Asahi Kasei Pharma Corporation aimed at producing clinical drug substance for antibody-based therapies.

Impilo Therapeutics, Inc. (referred to as "Impilo"), a privately-owned enterprise specializing in drug discovery and development, has officially launched its operations with a core mission to facilitate the effective utilization of nucleic acid-based medicines for the treatment of solid tumor cancers.

Nexus Pharmaceuticals has announced its receipt of approval from the U.S. Food and Drug Administration (FDA) for Potassium Chloride for Injection Concentrate, USP in 10mL and 20mL Single-Dose Vials.

Asieris Pharmaceuticals (688176) is a prominent global biopharmaceutical firm specializing in the research, development, and commercialization of novel drugs targeting genitourinary tumors and related ailments.

Antengene Corporation Limited (SEHK: 6996.HK), a prominent global biopharmaceutical company focused on innovative therapies in hematology and oncology

Rising Pharmaceuticals, a subsidiary of Rising Pharma Holdings Inc., has announced the approval, launch, and immediate availability of Edetate calcium disodium injection, addressing a critical shortage of this vital therapy in the United States.

Brenntag, a prominent global player in the distribution of chemicals and ingredients, has announced a strategic collaboration with audit provider Qualifyze.

Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), a pioneering clinical stage biopharmaceutical company dedicated to advancing innovative treatments for brain health disorders, has announced a strategic license agreement with Catalent

Roche today announced the expansion of their Global Business Partnership Agreement with Sysmex. As part of the renewed framework, the companies strengthen their commitment

NeuroBo Pharmaceuticals, Inc. a clinical-stage biotechnology company on a quest to transform cardiometabolic diseases, today announced that it has entered into a term sheet with MThera

Tyra Biosciences, Inc.a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor

Alpenglow Biosciences has been awarded a $1.6M grant to develop artificial intelligence (AI) enabled smart microscopy using its patented multi-resolution 3Di platform for 3D spatial biology.

Harrow a leading U.S. eyecare pharmaceutical company, today announced the completion of the transfer to Harrow of the New Drug Application for VIGAMOX® 0.5%, a fluoroquinolone antibiotic

Astellas Pharma Inc. today announced that the Center for Drug Evaluation of the China National Medical Products Administration (NMPA) has accepted the Biologics License Application

Ionis Pharmaceuticals, Inc. today announced it has expanded its existing collaboration with AstraZeneca to include exclusive rights for AstraZeneca to commercialize eplontersen in Latin

Biosion USA, Inc. a global clinical-stage R&D biotechnology company, today announced the phase 2 study initiation for the evaluation of BSI-045B, an anti-TLSP mAb, in the treatment of atopic dermatitis.

Today, the U.S. Food and Drug Administration approved RiVive, 3 milligram (mg) naloxone hydrochloride nasal spray for over-the-counter (OTC), nonprescription use for the emergency treatment of known or suspected opioid overdose.

KORU Medical Systems, Inc., a leading medical technology company focused on the development of innovative and easy-to-use subcutaneous infusion solutions, today announced an agreement with a biopharmaceutical company to validate

WuXi Vaccines, a leading global vaccine CDMO (Contract Development and Manufacturing Organization), today announced the successful GMP release of its CHO cell-based drug substance (DS) manufacturing facility located in Suzhou

Bio-Rad Laboratories, Inc. and QIAGEN N.V., today announced that the companies have agreed to settle their patent dispute pending in the U.S. District Court of Delaware pursuant to a global settlement and patent cross-licensing agreement relating

Everest Medicines, a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, announced today XERAVA

Clinical stage Australian biotech company HaemaLogiX Ltd is pleased to announce it has entered into a co-development agreement with the world leading Peter MacCallum Cancer Centre

InnoCare Pharma a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Company has received approval to conduct

Astellas Pharma Inc. and PeptiDream Inc.today announced a research collaboration and license agreement to discover novel protein degraders for two targets selected by Astellas. Under the

Cybin Inc.company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce that its Phase 2 trial

ImmunoBiochem Corporation, a privately-held biopharmaceutical company focused on the discovery of unique tumor targets and development of novel biological therapeutics, announced

BeiGene a global biotechnology company, today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion

SunHo BioPharmaceutical Co., Ltd.a clinical-stage leading biopharmaceutical company in immunocytokines with full-set of capabilities from discovery to commercialization, announced

MaaT Pharma, a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM dedicated to improving survival outcomes for patients

Riparian Pharmaceuticals, a Viva Biotech portfolio company, is a biotechnology company focused on discovering novel therapeutics for cardiovascular diseases. Riparian today announced it has entered into an exclusive license agreement and research agreement with Pfizer.

Approved for Public Release, Distribution Unlimited — The Defense Advanced Research Projects Agency (DARPA) announced that Ginkgo Bioworks which is building

Gannex Pharma Co., Ltd. a wholly-owned company of Ascletis Pharma Inc.announces today the completion of enrollment of 98 patients with primary biliary cholangitis

Santen Pharmaceutical Co.,Ltd.announced today that it has signed licensing agreements and an asset transfer agreement with two U.S. companies.

Endo International plc announced today that its Par Sterile Products business has begun shipping bivalirudin injection in a ready-to-use 250 mg/50 mL single-use vial. It is the only ready-to-use liquid format of bivalirudin on the market in the U.S.

Umitomo Chemical Co., Ltd, one of Japan's leading chemical companies, and Ginkgo Bioworks which is building the leading platform for cell programming and biosecurity,

Beckman Coulter Diagnostics, a leader in clinical diagnostics, and Fujirebio, a leader in neurological markers and in vitro diagnostics, announced today the formation of a new

Scipher Medicine today announced that it has entered into a multi-disease area collaboration with Ionis Pharmaceuticals. In the collaboration, Ionis is responsible

Sangamo Therapeutics, Inc a genomic medicine company, today announced it has signed an evaluation and option agreement with Prevail Therapeutic a wholly owned

TauRx Pharmaceuticals Ltd., a global leader in Tau-based research in Alzheimer’s disease today announced results from a prespecified analysis of the Phase 3 LUCIDITY

Eli Lilly and Company and Versanis Bio today announced a definitive agreement for Lilly to acquire Versanis, a private clinical-stage biopharmaceutical company focused on the development of new medicines for the treatment of cardiometabolic diseases.

Acadia Pharmaceuticals Inc. today announced that it has expanded its current licensing agreement for trofinetide with Neuren Pharmaceuticals to acquire ex-North American

KSQ Therapeutics, Inc. a clinical-stage biotechnology company developing cancer therapies using its proprietary CRISPRomics® discovery platform, announced today

Credible, a San Francisco-headquartered, AI-powered ESG Company has onboarded Ajanta Pharma Ltd, a leading global pharmaceutical company to improve its ESG

Liminal BioSciences Inc.and Structured Alpha LP a fund managed by Thomvest Asset Management Ltd., today announced that they have entered into a definitive arrangement

Bridge Biotherapeutics, a South Korean clinical-stage biotech company developing novel drugs for fibrosis, cancer and inflammation, announced that it has joined PROLIFIC, the Prognostic Lung Fibrosis Consortium, an organization devoted to boosting scientific exploration

Redwood Scientific Technologies Inc., a pioneering pharmaceutical company based in New York, is proud to announce the filing of a new patent for its cutting-edge Oral Thin Film (OTF) manufacturing system. The patent showcases Redwood's commitment to revolutionizing

Zhejiang Doer Biologics Co., Ltd. a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and cancers, today announced that it has entered into a license agreement with BioNTech SE.

Astellas Pharma Inc. and 4D Molecular Therapeutics, Inc. today announced a license agreement under which Astellas gains rights to utilize the intravitreal retinotropic R100*

Today, the US Food and Drug Administration converted the approval process for Leqembi indicated for the treatment of adult patients with Alzheimer's disease, is on traditional approval after a confirmatory study verified clinical benefit.

NS Pharma, Inc. announced today the U.S. Food & Drug Administration has granted Rare Pediatric Disease Designation to NS-089/NCNP-02 (brogidirsen) an investigational candidate for patients with Duchenne muscular dystrophy amenable to exon 44 skipping therapy.

South Rampart Pharma, Inc. a clinical-stage life science company advancing innovative medications for the treatment of pain, today announced that the China National Intellectual

Asieris Pharmaceuticals a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related

BioArctic AB's partner Eisai announced today that the U.S. Food and Drug Administration, FDA, has approved the supplemental Biologics License Application, sBLA, supporting the traditional

Novavax, Inc.a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, has been granted full Marketing Authorization by the European Commission

Pheon Therapeutics a leading Antibody-Drug Conjugate specialist developing next generation ADCs for a wide range of hard-to-treat cancers, today announces an exclusive licence agreement

Ascentage Pharma announced today that the company's core product Orebatinib has obtained clinical trial approval from the Center for Drug Evaluation of the National Medical Products

Astellas Pharma Inc. today announced that the U.S. Food and Drug Administration has accepted and granted Priority Review for the company’s Biologics License Application for zolbetuximab

InnoCare Pharma a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today the first psoriasis patient has been dosed in clinical trial

Taiho Oncology Europe GmbH and Taiho Pharmaceutical Co., Ltd., announced today that the European Commission has granted conditional marketing authorization for LYTGOBI® monotherapy for the treatment of adult patients with locally advanced or metastatic

Amneal Pharmaceuticals, Inc. today announced the launch of its authorized generic for Xyrem®1 oral solution CIII in the United States. Sodium Oxybate oral solution, 0.5 g/mL is a central nervous

ARUP Laboratories today announced that the U.S. Food and Drug Administration has approved AAV5 DetectCDx™ as a companion diagnostic to aid in the selection of adult patients eligible for treatment with ROCTAVIAN™ (valoctocogene roxaparvovec-rvox). ROCTAVIAN™, a new gene

Alloy Therapeutics, a biotechnology ecosystem company, announced the launch of its novel AntiClastic™ Antisense Oligonucleotide (AntiClastic ASO) platform, which employs optimally created spatial conformation nucleic acids that further enhance the drug-like properties

TME Pharma N.V. a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment, announces a positive clinical update on the survival of first-line glioblastoma patients in the GLORIA expansion arm evaluating NOX-A12,

Allecra Therapeutics announced today the submission of a New Drug Application to the U.S. Food and Drug Administration for cefepime/enmetazobactam, an antibiotic combination of the fourth

Pharmadule Morimatsu and WuXi Biologics officially entered into a global strategic cooperation for the Singapore CRDMO Center project of WuXi Biologics.

Savara Inc. a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that enrollment has been completed for the pivotal Phase 3 IMPALA-2 trial.

NephroDI Therapeutics (NephroDI), a pharmaceutical company focusing on concentration disorders of the kidney, announces today it has entered an agreement with The McQuade Center for Strategic Research and Development, LLC (MSRD), a member of the global Otsuka family

Spaulding Clinical, a leading clinical research organization (CRO), is expanding its services to include ADME (absorption, distribution, metabolism, and excretion) clinical trials. This strategic addition further solidifies Spaulding Clinical’s commitment

Aisa Pharma, Inc. a private, clinical-stage biopharmaceutical company today announced initiation of Part 2 of the RECONNOITER Phase 2 study, evaluating Profervia®, a once-daily novel, oral

Virpax® Pharmaceuticals, Inc. a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders

Simulations Plus, Inc., a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced the acquisition of Immunetrics, Inc. (“Immunetrics”), a modeling and simulation

Biolinq Incorporated, a medtech company that is developing novel biosensing technologies, has signed an exclusive license agreement with Taisho Pharmaceutical Co., Ltd., to commercialize a new generation of glucose monitoring products in Japan.

Freya Pharma Solutions, a pharmaceutical company dedicated to developing effective pharmaceutical therapies for women diagnosed with Female Sexual Disorders announced today

Arcellx, Inc. a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, announced

RK Pharma Inc, a vertically integrated pharmaceutical company today announced the successful completion of the acquisition of VGYAAN Pharmaceuticals LLC. The acquisition of VGYAAN Pharmaceuticals aligns strongly with our growth strategy

Oliva Therapeutics, LLC, a healthcare company focused on product commercialization, sales, marketing, distribution, and promotion, announced today a long-term partnership with Rio Biopharmaceuticals, Inc., a subsidiary of the EMS S/A Pharma

Astellas Pharma Inc. and Cullgen Inc. today announced a research collaboration and exclusive option agreement to discover multiple innovative protein degraders.

Eyebiotech Limited a clinical-stage ophthalmology biotechnology company, today announced the dosing of the first participants in its Phase 1b/2 AMARONE clinical trial in patients with diabetic

Future Fields, a pioneering biotechnology company that has built the world’s first synthetic biology system to use fruit flies for recombinant protein production, and Jenthera Therapeutics, a gene editing company focused on delivery of the CRISPR ribonucleoproteins

ACROBiosystems, through ACRO Certify and under its Aneuro brand, recently announced the launch of in vivo electrophysiology solutions for neuroscience research with Diagnostic Biochips. Together, two companies are committed to a collaborative

Veristat, a scientific-minded global clinical research organization, has acquired Scinopsis, a European medical writing consultancy with a 17-year track record of delivering regulatory

Lantern Pharma Inc. an artificial intelligence company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning platform with multiple

Cyclo Therapeutics, Inc. a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases,

DTx Pharma, a biotechnology company addressing the delivery challenges of oligonucleotide therapeutics with its Fatty Acid Ligand Conjugated OligoNucleotide platform, today announced

MAK-System, a worldwide leader in Blood Management systems, is proud to announce an extended and strategic partnership with New York Blood Center Enterprises

Sol-Gel Technologies, Ltd. an Israel-based dermatology company and Searchlight Pharma Inc. a private Canadian specialty pharmaceutical company, today announced the signing of exclusive

Propanc Biopharma, Inc. a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced the Company’s strategic

Ellipses Pharma a global drug development company focused on accelerating the development of new oncology treatments, today announces its intention to expedite further global clinical

Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for regenerating bone and managing infection in bone and soft

Agilent Technologies Inc.today announced new mass spectrometry solutions on show at the 71st ASMS Conference on Mass Spectrometry and Allied Topics, being held June 4 - 8 in Houston

Eikon Therapeutics, Inc., a biotechnology company that is advancing breakthrough therapeutics through the purposeful integration of engineering and science, today announced it has acquired

Crowell & Moring International is joining forces with Roche, TogetHER for Health, CAPED and Jhpiego to raise awareness about the surge of breast and cervical cancer cases in the Asia-Pacific

InDex Pharmaceuticals Holding AB today announced that a license agreement has been signed with Viatris Pharmaceutical Japan Inc.to register and commercialize cobitolimod in Japan

Pfizer Inc. announced today that the U.S. Food and Drug Administration has approved ABRYSVO™ the company’s bivalent RSV prefusion F vaccine, for the prevention

MEI Pharma, Inc. today confirmed receipt of an unsolicited and non-binding proposal on May 23, 2023 from a group represented by Anson Advisors Inc. and Cable Car Capital LLC, as referenced

Aragen Life Sciences , a leading Contract Research and Development Organization, and FAR Biotech, a US-based, AI-driven, computational drug discovery company, have announced

Algiax Pharmaceuticals, today provided an update on its ongoing Phase 2a study with lead candidate AP-325 in patients with chronic neuropathic pain. As part of a planned mid-enrollment

ME Pharma N.V. a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment , announces the American Society of Clinical

Abiogen Pharma S.p.A., Italian leading company in the field of osteoarticular and bone metabolism diseases, is pleased to announce the acquisition of a 97,09% stake in EffRx Pharmaceuticals SA,

Takeda Limited today announced that the U.S. Food and Drug Administration has granted priority review of the New Drug Application (NDA) for fruquintinib, a highly selective and potent inhibitor

TME Pharma NV a biotechnology company specializing in the development of novel therapies for the treatment of cancer by targeting the tumor microenvironment, announces that the American

AbCellera today announced a CA$701 million co-investment with the Governments of Canada and British Columbia to build new capabilities and infrastructure to develop innovative antibody-based

Touchlight, a company pioneering enzymatic DNA production, a critical material in many new genetic medicine treatments, has completed the redevelopment and expansion of its UK

Cumberland Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug Application

Freenome, a privately held biotech company, announced today it has acquired Oncimmune Ltd, a UK-based global immunodiagnostics developer with a commercialized CE-IVD marked EarlyCDT

Opentrons, a leader in lab automation, announces the launch of its Opentrons Flex robot, a new generation of affordable and easy-to-program liquid-handling lab robots designed to level the playing

Asieris Pharmaceuticals , a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related

ImaginAb, Inc., a global biotechnology company focused on the development of radiopharmaceuticals for the diagnosis and treatment of cancer, today announced lead selection

Xscientia plc today announced that Sumitomo Pharma Co., Ltd. plans to initiate a Phase 1 clinical study of DSP-2342 in the United States. DSP-2342 is a highly-selective bispecific small molecule

HiST Pharma through its wholly-owned Psoriasis Research Institute of Guangzhou announces today that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug

Juno Pharmaceuticals Canada a leader in the commercialization of specialty pharmaceuticals, announced the acquisition of Omega Laboratories one of Canada’s largest domestic specialty

Melinta Therapeutics, LLC and Xediton Pharmaceuticals Inc (Xediton) today announced they have entered into an exclusive commercialization and licensing agreement for BAXDELA®

Astellas Pharma Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved VEOZAHTM (fezolinetant) 45 mg once daily for the treatment of moderate to severe

Kintor Pharmaceutical Limited a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced that the Phase II clinical trial of in-house

Angelini Pharma, part of the privately owned Angelini Industries, and JCR Pharmaceuticals Co., Ltd. announced today that they entered into an exclusive global development

Oncocross, a Seoul-based AI drug discovery and development biotech, announced the completion of phase 1 global clinical trial of OC514, a treatment targeting sarcopenia and other rare muscular

Transgene a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announced that the first patient has been dosed in Delivir, a Phase I clinical

Zanrong Pharmaceutical Technology Co., Ltd. today announced an agreement with Roche to acquire the global rights to ZN-A-1041, an oral small molecule HER2 inhibitor. Zanrong

Freya Pharma Solutions, a pharmaceutical company focusing on the development of effective pharmaceutical therapies for women diagnosed with Female Sexual Disorders (FSD), announced

Bruker Corporation today announced that is has closed the acquisition of ZONTAL Inc. an innovative platform provider for the digital transformation of the analytical laboratory,

Ascletis Pharma Inc. announces today that the China National Medical Products Administration has approved to conduct a Phase IIa clinical trial for ASC10 to treat respiratory syncytial virus

Tetra Pharm Technologies develops and manufactures pharmaceutical drugs targeting the endocannabinoid system for the treatment of neuropathic pain, sclerosis and mental health disorders.

OncoHost, a technology company transforming the approach to precision medicine for improved patient outcomes, today announced that it has signed an option agreement with BGN

XNK Therapeutics AB today announced that the company's autologous natural killer (NK) cell therapy candidate XNK04 will be evaluated in combination with an ADCC competent PD-L1 inhibitor

Reprocell USA, a CRO, has been awarded a contract to provide support for Lantern Pharma's Phase 2 clinical trial entitled "A Study of LP-300 With Carboplatin and Pemetrexed in Never

BioCentriq, Inc. and panCELLa, a Pluristyx Company, announced that they have signed a research agreement designed to evaluate the ability of panCELLa's genetically-engineered, induced Pluripotent Stem Cell (iPSC)-derived

Fusion Pharmaceuticals Inc., a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the opening of its state-of-the-art radiopharmaceutical manufacturing facility. The 27,000 square foot good manufacturing practice (GMP) compliant facility

Tempus, a leader in artificial intelligence and precision medicine, today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s first Premarket Approval (PMA) application for its companion diagnostic test, xT CDx. xT CDx is a 648-gene next-generation sequencing test for solid tumor profiling

Guided Therapeutics, Inc. or the “Company”, the maker of LuViva, a rapid and painless cervical cancer detection system based on the Company’s patented biophotonic technology, provided an update regarding the start of its pivotal clinical trial. The results of this clinical study will be used to support the Company’s application for U.S. FDA approval

Ubie Inc. has signed a comprehensive collaboration agreement with Takeda Pharmaceutical Co., Ltd. to promote digital transformation, which aims to guide people to appropriate medical care for rare diseases and gastrointestinal diseases. Since April 2021, Ubie and Takeda Pharmaceutical Co., Ltd. have been promoting digital transformation

RNAimmune, Inc., a biopharmaceutical company specializing in discovery and development of mRNA-based therapeutics and vaccines, today announced that the Company has received a clearance from the United States Food & Drug Administration (FDA) cleared its Investigational New Drug (IND) application a Phase I clinical trial for RV-1730

TransCode Therapeutics, Inc., a leading clinical-stage oncology company committed to using its proprietary platform delivery system to defeat cancer, today announced a strategic expansion of its diverse product portfolio. New capabilities for TransCode’s TTX delivery platform are embodied

Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion and recommended granting a marketing authorization for Cosentyx® (secukinumab) in adults with active moderate to severe hidradenitis suppurativa (HS).

AMO Pharma Limited a privately held biopharmaceutical company focusing on rare childhood-onset neurogenetic disorders with limited or no treatment options, today announced completion

Global private investment firm, Bridgewest Group, recognized for developing innovative companies in life sciences, software, and deep tech, establishes LumaCina business unit under Bridgewest

Ascentage Pharma a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis Band age-related diseases, today announced that it recently

TraceLink Inc., the leading digital network platform company connecting more than 290,000 entities across the Healthcare and Life Sciences industry, today announced Multienterprise Information

Navamedic ASA a Nordic pharma company and provider of high-quality products to hospitals and pharmacies, has today amended its cash offer to acquire all shares in Sensidose AB

Evoke Pharma, Inc., a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced that the United States Patent and Trademark Office

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced completion of the safety evaluation stage of the highest dose cohort of patients with acute myeloid leukemia (AML) who relapsed after or were refractory

Zucara Therapeutics Inc., a diabetes-focused life sciences company developing the first once-daily therapeutic to prevent hypoglycemia (low blood glucose levels) in people with diabetes, today announced that the U.S. Food and Drug Administration ("FDA") has cleared the Company's Investigational New Drug ("IND") application for ZT-01 for the prevention

Ajinomoto Bio-Pharma Services, a leading provider of biopharmaceutical contract development and manufacturing services, is pleased to announce that the United States Food and Drug Administration (FDA) has approved the company's high potency vial line to manufacture a commercial product.

Nordic Capital has agreed to acquire a majority share in corpuls to support the Company's next phase of growth, in partnership with the founding family. corpuls is an innovative medical

Everest Medicines a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, announced today that it has signed

AbbVie announced that the U.S. Food and Drug Administration (FDA) has approved expanding the indication of QULIPTA® (atogepant) for the preventive treatment of migraine in adults. The approval makes QULIPTA the first and only oral calcitonin gene-related peptide (CGRP) receptor antagonist approved to prevent episodic and chronic migraine.

Eli Lilly and Company announced today that it will invest an additional $1.6 billion and add another 200 new jobs at its two new manufacturing sites within LEAP Innovation Park in Boone County, bringing the company's total commitment to $3.7 billion and up to 700 new jobs. The company also today committed $15 million over five years to the Ivy Tech

Mission Bio, Inc., the pioneer in high-throughput single-cell DNA and multi-omics analysis, today announced that it has entered into an agreement with Fulgent Genetics a technology-based

LyGenesis, Inc., a clinical-stage biotechnology company developing allogenic cell therapies for large unmet needs, and Imagine Pharma, a biotechnology company focused on the development

MGC Pharmaceuticals Ltd, a European based pharmaceutical company specializing in the development and supply of affordable, ethically produced plant-inspired medicines, announces

Sumitomo Pharma Oncology, Inc., a clinical-stage company focused on novel cancer therapeutics, today announced the U.S. Food and Drug Administration granted Orphan Drug Designation

Nuance Pharma announces dosing of first patient in the ENHANCE - China Phase III Trial for the maintenance treatment of chronic obstructive pulmonary disease of its novel solution Ensifentrine in mainland China.

Torrent Pharma has begun shipping the generic version of Xeris's Keveyis®, 50mg tablets, following final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application.

SciSparc Ltd., a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced it has been granted final approval from the Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, required to commence the Company’s Phase IIb Clinical Trial for SCI-110 to treat Tourette Syndrome

Dipharma Francis S.r.l., a global CDMO and leading manufacturer of New Chemical Entities (NCE), Generic Active Pharmaceutical Ingredients and advanced Intermediates, announced today the completion of the expansion of its Research and Development Center for small molecules at its Headquarters located in Baranzate, close to Milan

Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, today announced interim data demonstrating the potential of CPI-818, the Company’s ITK inhibitor, for the treatment of T cell lymphoma (TCL) at the 10th Whistler Global Summit on Hematologic Malignancies, which took place March 29 to April 2, 2023 in Whistler British Columbia, Canada

Genenta Science, a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, today announced that the license agreement with Ospedale San Raffaele (OSR) has been amended and restated to provide access to all solid tumor indications

REGiMMUNE Limited, a biotechnology company focused on developing innovative immunotherapies for immune disorders and cancer, and San Fu Biotech, a subsidiary of San Fu

CMP Pharma announced today that in order to mitigate drug shortage concerns, the FDA's CDER Office of Compliance has granted a shelf life extension for CMP Development LLC Potassium

Athos Therapeutics, Inc. a clinical-stage biotechnology company pioneering the development of artificial intelligence-based precision small molecule therapeutics for patients with autoimmune

Medical technology company Scivita Medical Technology Co., Ltd. and Boston Scientific one of the leading medical technology companies worldwide, have officially signed a Strategic Agreement

Astellas Pharma Inc. today announced that it has entered into an agreement with Roche Diabetes Care Japan Co., Ltd. for the development and commercialization of Roche Diabetes Care's

Celularity Inc. a biotechnology company developing placental-derived allogenic cell therapies and biomaterial products announces that it has entered into an exclusive distribution agreement

Aadi Bioscience, Inc. a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR

Pherecydes Pharma a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, announces that it has been selected for the 2023

Mitsubishi Tanabe Pharma America, Inc. today announced it has completed enrollment for the global, multi-center, double-blind, Phase 3b study evaluating the long-term efficacy and safety

FSD Pharma Inc. a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory

TaiGen Biotechnology Company, Limited today announces that they have signed an exclusive licensing agreement with Joincare Pharmaceutical Group Industry Co., Ltd., a top 10 China

Jacobio Pharma announced it has entered into a clinical collaboration with Merck & Co., Inc., Rahway, NJ, USA to evaluate the combination of Jacobio's CD73 monoclonal antibody JAB-BX102

The 2023 Annual Meeting of American Academy of Dermatology Association was held from 17 to 21 March 2023 in New Orleans, Louisiana, United States. As one of the largest, most influential

Stevanato Group S.p.A. a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced

Labstat Inc., A Certified Group Company, has entered into a partnership with Toxys to offer the ToxTracker assay at its Kitchener, Ontario laboratory. ToxTracker is a state-of-the-art stem

DelSiTech Ltd, a Finnish drug delivery and drug development company, today announces that it has been awarded a grant from the Bill & Melinda Gates Foundation to develop

Nippon Express a group company of NIPPON EXPRESS HOLDINGS, INC., became the first Japanese forwarder to join Pharma.Aero on January 25 this year.

Optimism is on the rise as the American Cancer Society is reporting that the five-year survival rate for those diagnosed with pancreatic has increased to 12%—representing an increase of 1% over

Astellas Pharma Inc. today announced positive topline results from the Phase 3 China ARCHES study of XTANDI® plus androgen deprivation therapy in men with metastatic hormone-sensitive

On March 7th, 2023, Suzhou Porton Advanced Solutions Ltd. and Bennu Biotherapeutics announced a strategic partnership to advance cell and gene therapy R&D pipelines.

Sumitovant Biopharma Ltd.and Myovant Sciences Ltd. announced today that Sumitovant has successfully completed its acquisition of Myovant originally announced October 23, 2022.

Endo International plc announced today that one of its operating companies, Par Pharmaceutical, Inc., has begun shipping the first generic version of Allergan's Pylera® 140 mg, 125 mg and 125

Shuttle Pharmaceuticals Holdings, Inc.a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with

Microbion Corporation today announced that a Phase 2, randomized, controlled study has been initiated to assess the safety and efficacy of topical pravibismane for the treatment of subjects

InvoX Pharma Limited a U.K.-based wholly-owned subsidiary of Sino Biopharmaceutical Limited with an advancing pipeline of innovative products, today announces that it has successfully

IBSA Pharma announced today that it has entered into an agreement with Mark Cuban Cost Plus Drug Company, PBC to offer Tirosint® oral capsules at a low cash price via the Cost Plus Drugs

On the eve of International Women’s Day, BioSyent Inc. celebrates the Canadian launch of FeraMAX® Pd Maintenance 45 by its subsidiary, BioSyent Pharma Inc. FeraMAX® Pd

Sun Pharmaceutical Industries Limited today announced the successful completion of its acquisition of Concert Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical

Harbour BioMed a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunology,

Finding easy-to-understand information about pediatric liver diseases that even kids can relate to has been a challenge, that's why the American Liver Foundation is launching a new pediatric liver

Sanyou Biopharmaceuticals, a leading provider of biotech CRDMO services, is opening a new office in Cambridge Innovation Centre, CIC, marking a new era towards the company's rising ambition on serving and collaborating with world's best biotech start-ups and ventures.

The pioneer of innovative proteomic and glycomic research solutions, today announced the acquisitions of Click Chemistry Tools, a manufacturer of click chemistry linkers and labeling

The ERP Biomarker Qualification Consortium announced today the successful completion of a pharma industry-sponsored study to measure the electrophysiologic effects of ketamine on healthy brain function.

ArisGlobal , the leading provider of life sciences software that automates the core functions of drug development with its end-to-end LifeSphere® LifeSphere® technology platform, today announced

NATCO Pharma Limited announces launch of Pomalidomide Capsules in Canada, the first generic alternative to POMALYST® brand in the country approved by Health Canada. Pomalidomide is used in combination with Dexamethasone and Bortezomib for the treatment of adult patients

Tempus, a leader in artificial intelligence (AI) and precision medicine, today announced a multi-year, strategic collaboration with Pfizer in which the two companies are working together to further AI and machine learning-driven efforts in therapeutic development. The goal of this collaboration

AMO Pharma Limited, a privately held biopharmaceutical company focusing on rare childhood-onset neurogenetic disorders with limited or no treatment options, today announced that the UK

Mitsubishi Tanabe Pharma America, Inc. today announced the publication of results from the global, multi-center, open-label, Phase 3 clinical trial evaluating the long-term safety

TransCode Therapeutics, Inc., the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the signing of a non-binding letter of intent and a joint research and development agreement (JDA) with industrial biotechnology and genome editing expert, BRAIN Biotech AG

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body, announced today a collaboration and option agreement with Ono Pharmaceutical Co., Ltd. (“Ono”), for CUE-401, a bispecific protein

Pharmatech Associates today announced a strategic alliance that brings PCM expertise and capabilities to the marketplace to tackle drug shortages and supply chain issues by providing drug sponsors and manufacturers a more effective means of making finished drug products

MMS Holdings, a data-focused contract research organization (CRO) – announced its partnership with the Institute for Advanced Clinical Trials (I-ACT) to accelerate the development of life-saving therapeutics, including vaccines, medicines, and medical devices for children.

Biocytogen Pharmaceuticals Co., Ltd. today announced the launch of the “Nano 100 Project”, which aims to develop fully human nanobody drugs for over 100 targets. The Project combines

Theragent, a cell therapy CDMO focused on advancing next-generation cancer and rare disease treatments, has signed a multi-year exclusive contract with Insight68, an AI-driven software provider

NS Pharma, Inc. announced today the first patient enrollment in a Phase 2 clinical study of NS-018 an investigational treatment for myelofibrosis a rare and incurable blood cancer.

National Resilience, Inc., a technology-focused manufacturing company dedicated to broadening access to complex medicines, today announced a 10-year biomanufacturing partnership with a leading pharmaceutical company for its portfolio of services across Process and Analytical Development, Drug Substance, and Drug Product manufacturing

Renexxion Ireland Limited, a private biopharmaceutical company committed to providing innovative medicines to patients with high unmet need for gastrointestinal disorders, will is pleased to

Taiwan-based Formosa Pharmaceuticals announced today that the company has entered into a collaboration agreement with Eyenovia, Inc. for the development of novel ophthalmic therapeutics.

GreenLab, Inc. announces launch of the biotech startup's proprietary vector technology platform. GreenLab Vector Technology greens recombinant protein manufacturing by transforming novel

As federal authorities widen a multistate investigation into antibiotic-resistant Pseudomonas aeruginosa bacterial contamination linked to EzriCare Artificial Tears eye drops, a woman has now filed a federal lawsuit against EzriCare and retailer Walmart after using the eye drops and suffering

ESSA Pharma Inc. a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that further analyses of initial clinical data

PharmaNutra S.p.A. a company specialised in mineral and iron-based nutritional supplements and medical devices for muscles and joints, is ready to face the great challenge of the FIA World

Roche today announced that it has expanded its collaboration with Janssen Biotech Inc. to create companion diagnostics for targeted therapies, further strengthening research and innovation activities.

Astellas Pharma Inc. today announced its commitment to achieve net zero greenhouse gas emissions by 2050.Astellas Pharma Inc. today announced its commitment to achieve net zero greenhouse gas emissions by 2050.

Envision Pharma Group a leading global technology-enabled commercialization, integrated medical capabilities and solutions, and data analytics partner to the life sciences industry, announced

Kenya Medical Research Institute NEC Corporation and Nagasaki University have developed an immunization management system based on digital biometrics for newborns in Kenya. Validation

Ellipses Pharma, a global drug development company focused on accelerating the development of cancer medicines and treatments through an innovative drug development model, today announces that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for EP0042

Seqens Group, an integrated leader in the development and manufacture of active pharmaceutical ingredients (APIs) and intermediates, today announced that it has opened Seqens Boston R&D Center, a state-of-the-art, 15,000 square-foot R&D center in Devens, Mass. Serving as one of the company’s global centers

Ajinomoto Co., Inc.today announced a license agreement with Exelixis, Inc. to develop AJICAP , its proprietary site-specific bioconjugation and Linker Technology of Ajinomoto Co., in the development of certain Exelixis Antibody-Drug Conjugate programs.Exelixis is a commercially successful Exelixis is a commercially successful

Hemab Therapeutics, a clinical-stage biotechnology company developing next-generation therapeutics for serious, underserved bleeding and thrombotic disorders, today announced the first patient has been dosed in a Phase 1/2 study evaluating HMB-001 for the treatment of the severe bleeding disorder Glanzmann